Image-guided therapy developer IMRIS has regained compliance with listing requirements of the Nasdaq Global Market.
In August 2014, the company received a letter from Nasdaq stating that for the previous 30 consecutive business days, the bid price of its common stock closed below the minimum $1 per share required for continued listing.
However, on February 13, Nasdaq informed IMRIS that the closing bid price of its common stock had been greater than $1 for 10 consecutive business days, and it is once again in compliance with the market's listing rule.
